Cat. #161686
Jurkat Zip6KO
Cat. #: 161686
Availability: 8-10 weeks
Organism: Human
Tissue: PBMC
Model: Zip6KO
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Rub?n Vicente
Institute: Universitat Pompeu Fabra
Primary Citation: Colomar-Carando et al. 2019. J Immunol. 202(2):441-450. PMID: 30552163.
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Jurkat Zip6KO
- Cancer: Blood cancer
- Research fields: Cancer;Immunology
- Parental cell: Jurkat
- Organism: Human
- Tissue: PBMC
- Growth properties: Impaired Activation
- Model: Zip6KO
- Model description: CRISPR/Cas9âexpressing Jurkat cell line used to generate a Zip6KO Jurkat cell line
- Crispr: Yes
- Description: Cell line used to study how the absence of the Zip6 transporter affects lymphocyte physiology. Zip6 Knockout (KO) line, Zip6 is strongly upregulated early during activiation of T lymphocytes stimulated using anti-CD3/anti-CD28
- Production details: Cells were maintained in RPMI 1640 medium supplemented with 10% FBS and 1% penicillin/streptomycin. Where indicated, FBS was incubated according to the manufacturerâs instructions with Chelex 100 resin (Bio-Rad Laboratories) to generate Zn2+-free growth medium. Various amounts of ZnSO4 were added to the final medium to generate specific Zn2+ concentration conditions. Cells were grown at 37°C in a humidified 5% CO2 atmosphere.Â
Handling
- Growth medium: RPMI 1640 medium
- Temperature: 37° C
- Atmosphere: 5% CO2
- Shipping conditions: Dry Ice
- Cultured in antibiotics: 1% Penicillin-Streptomycin
References
- Colomar-Carando et al. 2019. J Immunol. 202(2):441-450. PMID: 30552163.
